Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: early-phase trial registry
5 of 10 indexed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: 10 US clinical trials tracked, 5 recruiting.
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 3 of these trials.
Enrollment posture brief
Registry condition diffuse-large-b-cell-lymphoma-not-otherwise-specified
OPEN 5 | RECR 50% | LATE 0 | EARLY 8 | RANK #1724 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified is recruiting above its size-band peers.
5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Diffuse Large B-Cell Lymphoma, Not Otherwise Specified research.
University of Washington accounts for 3 of 10 trials (30%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials plan to enrol fewer than 100 people.
Median target enrolment is 56 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.
-
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics
NCT06014762
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Academic and Community Cancer Research United
NCT06238648
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
NCT04231877
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Hua-Jay J Cherng, MD
NCT06693830
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT07097363
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
NCT03984448
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
NCT03656835
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
NCT03038672
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
NCT04257578
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
NCT03742258
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Diffuse Large B-Cell Lymphoma, Not Otherwise Specified records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diffuse Large B-Cell Lymphoma, Not Otherwise Specified page
10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Large B-Cell Lymphoma, Not Otherwise Specified condition card totals 10 registered trials; most-linked intervention Computed Tomography; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.